IndieBioA2A PharmaMay 16, 20191 min readUpdated: Feb 7, 2020IndieBio - Designing Drugs insilico: An Interview with Ed Painter of A2A PharmaceuticalsLEARN MORE
A2A TACC3 Program Clinical Progress in Womens CancersMay 27, 2025 - A2A Pharmaceuticals a clinical stage oncology company with the lead asset AO-252, a PPI inhibitor of TACC3 which is a 1st...
A2A co-founded biomea Fusion raises $56MBiomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations...
Comments